PTC Therapeutics (PTCT) PT Lowered to $53 at JPMorgan, 'Late Stage Assets Remain Significantly Underappreciated'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
PTC Therapeutics (PTCT) PT Lowered to $45 at Truist Securities; 'PTC isn't dead'
September 18, 2023 6:14 AM EDTTruist Securities analyst Robyn Karnauskas lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $60.00) while maintaining a Buy rating.
THE analyst commented, "In addition to the negative CHMP decision, we believe concerns about cash position and mgmt's ability to... More
Raymond James Downgrades PTC Therapeutics (PTCT) to Underperform, 'expect the drug to be officially pulled from the EU market by January 2024'
September 15, 2023 9:06 AM EDT(Updated - September 15, 2023 9:18 AM EDT)
Raymond James analyst Danielle Brill downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Underperform.
The analyst comments "We are downgrading PTCT to Underperform following this mornings new release that the CHMP issued a negative opinion for the... More
PTC Therapeutics' (PTCT) Translarna Receives Negative CHMP Opinion
September 15, 2023 6:00 AM EDTPTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The negative opinion also applies to the renewal of the existing conditional authorization. PTC plans to submit a request for re-examination per EMA guidelines. Translarna will remain on the market and available to... More
